GEM-X Single Cell 5� Gene Expression Kits and Companion Reagents.
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98026Q01198 in this department, oldest first.
- Sep 11, 2026 · this noticePre-solicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
The National Institutes of Health (NIH) intends to award a Firm-Fixed-Price Purchase Order to 10x Genomics for GEM-X Single Cell 5� Gene Expression Kits and Companion Reagents. The Government intends to solicit from a single source in accordance with FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The requirement is for the following supplies: (2) GEM-X Universal 5� Gene Expression v3 Kits � 48 samples (2) GEM-X Universal 5� Gene Expression v3 Kits � 4 samples (4) Chromium GEM-X Single Cell 5� Chip Kits v3 � 4 chips (4) Dual Index Ki… (show all)
t TT Set A Kits � 96 reactions These kits and companion reagents will be used to analyze single-cell/single-nucleus gene expression profiles across approximately 96 individuals. The assays will complement data already collected from matched study participants using the 10x Genomics platform. Maintaining compatibility with the existing data and established assay workflow is necessary to ensure that the resulting data can be integrated and analyzed consistently with the previously collected datasets. The resulting resource will be used to identify molecular risk factors, regulatory mechanisms, and potential therapeutic targets for cardiometabolic diseases. 10x Genomics is the sole manufacturer and authorized source for the required GEM-X Universal 5� Gene Expression v3 kits and associated GEM-X single-cell reagents specified in this requirement. The required products are proprietary to 10x Genomics and are necessary to maintain compatibility with the existing 10x Genomics-based research workflow and previously collected data. This notice is not a request for competitive quotations. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required supplies and meet all specified technical and operational requirements. The Government will consider all timely capability statements received and determine whether the acquisition should proceed as a sole-source procurement or be competed. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source is capable of meeting the requirement. Capability statements shall be submitted electronically to haunp@mail.nih.gov no later than 9:00 a.m. EDT on September 21, 2026. Please reference Notice No. 75N98026Q01198 in the subject line of the response.
Who won similar work
4 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same NAICS 621511.
Single-winner award sizes (4): middle half $186K to $382K, median $281K; range $49K to $533K.
| Winner | Awards | Value | Last |
|---|---|---|---|
| PSOMAGEN INC | 1 | $533K | Dec 31, 2024 |
| University Of California, Los Angeles Los Angeles CA 90024 USA | 1 | $331K | Sep 29, 2025 |
| BAYLOR MIRACA GENETICS LABORATORIES LLC | 1 | $232K | Sep 26, 2025 |
| GREENWOOD GENETIC CENTER INC | 1 | $49K | Sep 25, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- Sep 29, 2025University Of California, Los Angeles Los Angeles CA 90024 USA$331KDNA Methylation Microarray Processing Services for the Baltimore Longitudinal Study of Aging (BLSA)No listed company matched (Materiality N/A)
- Sep 26, 2025BAYLOR MIRACA GENETICS LABORATORIES LLC$232KQ--Clinical TestingNo listed company matched (Materiality N/A)
- Sep 25, 2025GREENWOOD GENETIC CENTER INC$49KQ--Genetic Testing with Greenwood Genetic Center IncNo listed company matched (Materiality N/A)
- Dec 31, 2024PSOMAGEN INC$533KLong read sequencing servicesNo listed company matched (Materiality N/A)
Competitive landscape
For the 4 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 0 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.